New hope for CML patients: Real-World study tests asciminib after two failed treatments

NCT ID NCT06684964

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 28 times

Summary

This study follows 40 adults in Saudi Arabia with chronic-phase CML who have already tried two or more TKIs. Researchers will track how well asciminib controls the cancer, its side effects, and how it affects daily life. The goal is to see if this medication works in real-world settings, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Dammam, 15215, Saudi Arabia
Novartis Investigative Site
RECRUITING

Jeddah, 21423, Saudi Arabia
Novartis Investigative Site
RECRUITING

Riyadh, 11211, Saudi Arabia
Novartis Investigative Site
RECRUITING

Riyadh, 11426, Saudi Arabia

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE